Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

Carlton D. Dampier, Marilyn Jo Telen, Ted Wun, R. Clark Brown, Payal Desai, Fuad El Rassi, Beng Fuh, Julie Kanter, Yves Pastore, Jennifer Rothman, James G. Taylor, VI, David Readett, Krupa M. Sivamurthy, Brinda Tammara, Li-Jung Tseng, Jay Nelson Lozier, Helen Thackray, John L. Magnani, Kathryn L. Hassell

Blood (2023) 141 (2): 168–179.

https://doi.org/10.1182/blood.2022015797

Published: 2023

Includes: Supplemental data

Journal Articles

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Marilyn J. Telen, Ted Wun, Timothy L. McCavit, Laura M. De Castro, Lakshmanan Krishnamurti, Sophie Lanzkron, Lewis L. Hsu, Wally R. Smith, Seungshin Rhee, John L. Magnani, Helen Thackray

Blood (2015) 125 (17): 2656–2664.

https://doi.org/10.1182/blood-2014-06-583351

Published: 2015

Includes: Supplemental data

Journal Articles

An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia

Timothy L. McCavit, MD, MS, Lakshmanan Krishnamurti, MD, Lewis L. Hsu, MD, PhD, Charles T. Quinn, MD, MS, Isaac Odame, MD, Ofelia A. Alvarez, MD, Catherine Driscoll, MD, Kim Smith-Whitley, MD, Seungshin Rhee, MS, Ted Wun, MD, Marilyn J. Telen, MD, Helen Thackray, MD

Blood (2013) 122 (21): 2206.

https://doi.org/10.1182/blood.V122.21.2206.2206

Published: 2013

Journal Articles

Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease

Laura M. De Castro, MD, Ted Wun, MD, Sophie Lanzkron, MD MHS, Wally R. Smith, MD, Kathryn L. Hassell, MD, Abdullah Kutlar, MD, Kim Smith-Whitley, MD, Seungshin Rhee, MS, Marilyn J. Telen, MD, Helen Thackray, MD

Blood (2013) 122 (21): 775.

https://doi.org/10.1182/blood.V122.21.775.775

Published: 2013

Journal Articles

GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease

Marilyn J. Telen, MD, Ted Wun, MD, Timothy L. McCavit, MD, MS, Laura M. De Castro, MD, Lakshmanan Krishnamurti, MD, Sophie Lanzkron, MD, MHS, Lewis L. Hsu, MD, PhD, Wally R. Smith, MD, Seungshin Rhee, MS, John L. Magnani, PhD, Helen Thackray, MD

Blood (2013) 122 (21): 776.

https://doi.org/10.1182/blood.V122.21.776.776

Published: 2013

Journal Articles

Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State

John L. Magnani, PhD, Frans A Kuypers, PhD, John T. Patton, PhD, Sandra K Larkin, MS, Lori Styles, MD, Laura M DeCastro, MD, Marilyn J. Telen, MD, Ted Wun, MD, Helen Thackray, MD

Blood (2012) 120 (21): 87.

https://doi.org/10.1182/blood.V120.21.87.87

Published: 2012

Journal Articles

Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070

Scott I Simon, Shannon Chase, Helen Thackray, John L. Magnani, Ted Wun

Blood (2011) 118 (21): 851.

https://doi.org/10.1182/blood.V118.21.851.851

Published: 2011

Journal Articles

GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease

Lori Styles, MD, Ted Wun, MD, FACP, FRCPA, Laura M. De Castro, MD, Marilyn J. Telen, MD, William Kramer, PhD, Henry Flanner, John L Magnani, PhD, Helen Thackray, MD

Blood (2010) 116 (21): 1632.

https://doi.org/10.1182/blood.V116.21.1632.1632

Published: 2010

Journal Articles

Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study

Ted Wun, MD, Laura M. De Castro, MD, Lori Styles, MD, Anthony Cheung, MD, Shannon Chase, Scott I Simon, PhD, John L Magnani, PhD, Helen Thackray, MD

Blood (2010) 116 (21): 262.

https://doi.org/10.1182/blood.V116.21.262.262

Published: 2010

Journal Articles

Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In Crisis

Scott I Simon, PhD, Shannon Chase, Sandra K Larkin, Frans Kuypers, Ph.D., Lori Styles, MD, Ted Wun, MD, FACP, Helen Thackray, MD, John L Magnani, PhD

Blood (2010) 116 (21): 2672.

https://doi.org/10.1182/blood.V116.21.2672.2672

Published: 2010

NARROW

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia

Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease

GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease

Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State

Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070

GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease

Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study

Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In Crisis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only